What began as a routine adjustment in COPD treatment quickly turned into a medical mystery. Within just 48 hours of switching to a new inhaler, a 55-year-old woman developed painful, bright red patches across her face and neck, along with a mild fever. While the visible symptoms faded relatively quickly, further investigation revealed something far more unusual—Sweet syndrome, a rare immune-related skin disorder.
The patient had been stable for years on her previous medication, making the sudden reaction even more surprising. After ruling out infections, allergies, and autoimmune conditions, doctors performed a skin biopsy that confirmed the diagnosis. Once the inhaler was discontinued and corticosteroid treatment began, her symptoms improved rapidly, reinforcing the suspected link between the medication change and the reaction.
Sweet syndrome, also known as acute febrile neutrophilic dermatosis, is characterized by sudden onset of painful red lesions, often accompanied by fever and elevated white blood cell counts. It is typically associated with infections, certain cancers, or medications such as antibiotics and vaccines. However, cases linked to inhaled therapies have not been previously documented, making this situation particularly noteworthy.
This case highlights the importance of vigilance when introducing even commonly used medications. For healthcare providers, recognizing unusual symptoms following treatment changes can be critical for early diagnosis and effective care. It also serves as a reminder that even well-established therapies can carry rare and unexpected risks, underscoring the need for awareness, monitoring, and timely medical evaluation.
